Login to Your Account

Pharma: Clinic Roundup

Thursday, October 4, 2012
• Janssen Biotech Inc., of Horsham, Pa., a unit of Johnson & Johnson, reported data from the 52-week TRANSIT study at the European Academy of Dermatology and Venereology congress in Prague, Czech Republic, demonstrating that Stelara (ustekinumab) is effective, generally well tolerated and improves quality of life in patients with moderate to severe plaque psoriasis.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription